tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Gliosis D005911 6 associated lipids
Kidney Tubular Necrosis, Acute D007683 3 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Hallucinations D006212 4 associated lipids
Sleep Wake Disorders D012893 7 associated lipids
Rosacea D012393 13 associated lipids
Pericarditis D010493 6 associated lipids
Hyperpigmentation D017495 11 associated lipids
Autonomic Nervous System Diseases D001342 4 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Tachycardia, Ventricular D017180 9 associated lipids
Hypoxia-Ischemia, Brain D020925 22 associated lipids
Long QT Syndrome D008133 10 associated lipids
Intestinal Pseudo-Obstruction D007418 5 associated lipids
Mycoses D009181 18 associated lipids
Liver Failure D017093 5 associated lipids
Epilepsy, Temporal Lobe D004833 4 associated lipids
Retinoblastoma D012175 12 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Gastroenteritis D005759 4 associated lipids
Hypertrophy, Left Ventricular D017379 12 associated lipids
Inappropriate ADH Syndrome D007177 4 associated lipids
Lymphoma, B-Cell D016393 24 associated lipids
Lymphoma, T-Cell D016399 11 associated lipids
Cicatrix, Hypertrophic D017439 4 associated lipids
Pityriasis D010915 3 associated lipids
Hand Dermatoses D006229 5 associated lipids
Postoperative Hemorrhage D019106 7 associated lipids
Liver Abscess D008100 6 associated lipids
Carpal Tunnel Syndrome D002349 3 associated lipids
Foot Dermatoses D005533 3 associated lipids
Anus Diseases D001004 3 associated lipids
Endomyocardial Fibrosis D004719 4 associated lipids
Ataxia Telangiectasia D001260 6 associated lipids
Herpesviridae Infections D006566 4 associated lipids
Leukoencephalopathies D056784 3 associated lipids
Pouchitis D019449 3 associated lipids
Granuloma, Giant Cell D006101 7 associated lipids
Epstein-Barr Virus Infections D020031 3 associated lipids
Labyrinthitis D007762 2 associated lipids
Foot Deformities, Acquired D005531 2 associated lipids
Dermatomyositis D003882 2 associated lipids
Dementia, Vascular D015140 7 associated lipids
Mastocytosis D008415 5 associated lipids
Molluscum Contagiosum D008976 2 associated lipids
Paresis D010291 2 associated lipids
Intracranial Hypertension D019586 4 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Chronic Disease D002908 7 associated lipids
Drug-Related Side Effects and Adverse Reactions D064420 3 associated lipids
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Vitiligo D014820 2 associated lipids
Hemophilia B D002836 3 associated lipids
Myasthenia Gravis D009157 5 associated lipids
Hyperkalemia D006947 3 associated lipids
Intracranial Thrombosis D020767 2 associated lipids
Pemphigus, Benign Familial D016506 3 associated lipids
Skin Diseases, Vesiculobullous D012872 5 associated lipids
Prurigo D011536 4 associated lipids
Hepatitis, Viral, Animal D006524 4 associated lipids
Cryptococcosis D003453 3 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Simian Acquired Immunodeficiency Syndrome D016097 4 associated lipids
Castleman Disease D005871 3 associated lipids
Wounds, Stab D014951 3 associated lipids
Keratosis, Actinic D055623 3 associated lipids
Toxocariasis D014120 3 associated lipids
Fistula D005402 8 associated lipids
Confusion D003221 4 associated lipids
Encephalitis, Viral D018792 3 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Optic Nerve Injuries D020221 4 associated lipids
Hyperuricemia D033461 4 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Viremia D014766 4 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Tuberous Sclerosis D014402 2 associated lipids
Ocular Motility Disorders D015835 2 associated lipids
Pain, Intractable D010148 4 associated lipids
Sciatic Neuropathy D020426 13 associated lipids
Perceptual Disorders D010468 3 associated lipids
Polyneuropathies D011115 3 associated lipids
Heart Injuries D006335 6 associated lipids
Hearing Loss, Noise-Induced D006317 4 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Reflex Sympathetic Dystrophy D012019 4 associated lipids
Kartagener Syndrome D007619 2 associated lipids
Earache D004433 2 associated lipids
Delayed Graft Function D051799 2 associated lipids
Gingival Hyperplasia D005885 3 associated lipids
Intussusception D007443 1 associated lipids
Neoplasms, Second Primary D016609 4 associated lipids
Paraparesis, Tropical Spastic D015493 1 associated lipids
Crigler-Najjar Syndrome D003414 1 associated lipids
Apraxias D001072 1 associated lipids
Cholangitis, Sclerosing D015209 1 associated lipids
Venous Insufficiency D014689 2 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Swanson C et al. FK 506-based immunosuppression in clinical pancreas transplantation. 1995 Transplant. Proc. pmid:8539827
Watanabe K et al. Donor bone marrow cell facilitates induction of tolerance to kidney allografts in dogs treated with fractionated lymphoid irradiation and FK 506. 1991 Transplant. Proc. pmid:1703706
Kobayashi N et al. Significance of pancreatic allograft rejection in swine abdominal organ cluster transplantation. 1991 Transplant. Proc. pmid:1703707
Wu MJ et al. Reduced variability of tacrolimus trough level in once-daily tacrolimus-based Taiwanese kidney transplant recipients with high-expressive genotype of cytochrome P450 3A5. 2014 Transplant. Proc. pmid:24655974
Jun H et al. Experiences on conversion to once-daily Advagraf and sirolimus combination in stable kidney recipients. 2014 Transplant. Proc. pmid:24655973
Kumar MS et al. ATGAM versus OKT3 induction therapy in cadaveric kidney transplantation: patient and graft survival, CD3 subset, infection, and cost analysis. 1998 Transplant. Proc. pmid:9636549
Corry RJ et al. Tacrolimus without antilymphocyte induction therapy prevents pancreas loss from rejection in 123 consecutive patients. 1998 Transplant. Proc. pmid:9532157
Shimada H et al. Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression. 2000 Transplant. Proc. pmid:11119931
Vela CG et al. Prospective study of lipid disorders in FK506-versus cyclosporine-treated renal transplant patients. 2000 Transplant. Proc. pmid:10715453
Moochhala SM et al. Inhibition of drug metabolism in rat and human liver microsomes by FK 506 and cyclosporine. 1991 Transplant. Proc. pmid:1721277
Pan F et al. Effect of tacrolimus and splenectomy on engraftment and GVHD after bone marrow xenotransplantation in the reciprocal hamster to rat animal models. 1996 Transplant. Proc. pmid:8623373
Mazzaferro V et al. Studies of the hepatotrophic qualities of FK 506 and CyA. 1990 Transplant. Proc. pmid:1689913
Cofan F et al. Effect of calcineurin inhibitors on low-density lipoprotein oxidation. 2005 Transplant. Proc. pmid:16386540
Spagnoletti G et al. Cardiovascular risk profile in kidney transplant recipients treated with two immunosuppressive regimens: tacrolimus and mycophenolate mofetil versus everolimus and low-dose cyclosporine. 2009 Transplant. Proc. pmid:19460509
Rodrigo E et al. Higher initial tacrolimus blood levels and concentration-dose ratios in kidney transplant recipients who develop diabetes mellitus. 2005 Transplant. Proc. pmid:16386549
Land W et al. Mycophenolate mofetil monotherapy: an optimal, safe, and efficacious immunosuppressive maintenance regimen in kidney transplant patients. 2001 Transplant. Proc. pmid:11406265
Charco R et al. Hypercholesterolemia in long-term survivors of liver transplantation: a comparison between cyclosporine and FK 506. 1998 Transplant. Proc. pmid:9636605
Maggard M et al. Incidence of acute rejection in African-American liver transplant recipients. 1998 Transplant. Proc. pmid:9636607
Furlan V et al. Interaction between tacrolimus and itraconazole in a heart-lung transplant recipient. 1998 Transplant. Proc. pmid:9474996
Rucay P et al. FK 506 as treatment of late acute rejection in liver transplant patients. 1995 Transplant. Proc. pmid:7533354
Nishimori H et al. Combination therapy with FK 506 and splenectomy may induce tolerance in cardiac xenografts. 1994 Transplant. Proc. pmid:7518102
Schwartz M et al. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. The US Multicenter FK 506 Dose Optimization. 1995 Transplant. Proc. pmid:7533355
Katz HR et al. Mast cell biochemical and functional heterogeneity. 1991 Transplant. Proc. pmid:1721308
Yasuhara M et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living-related donor liver transplantations. 1995 Transplant. Proc. pmid:7533356
Ishibashi M et al. Elimination of the adverse effects of tacrolimus-based induction therapy by a 5-day exposure of optimal steady-state blood concentration in renal transplant patients in the early postoperative period. 1999 Transplant. Proc. pmid:10578281
de Paulis A et al. Antiinflammatory effect of FK 506 on human basophils. 1991 Transplant. Proc. pmid:1721309
Seymen P et al. Effects of cyclosporine-tacrolimus switching in posttransplantation hyperlipidemia on high-density lipoprotein 2/3, lipoprotein a1/b, and other lipid parameters. 2009 Transplant. Proc. pmid:20005364
Schuller S et al. Daclizumab induction therapy associated with tacrolimus-MMF has better outcome compared with tacrolimus-MMF alone in pediatric living donor liver transplantation. 2005 Transplant. Proc. pmid:15848653
Propper DJ et al. Low-dose FK 506 inhibits sensitisation after blood transfusions. 1990 Transplant. Proc. pmid:1697114
Tiebosch A et al. Side effects of FK 506 in cynomolgus monkeys: a histopathologic study. 1990 Transplant. Proc. pmid:1697115
Karabulut AB and Ara C Melatonin ameliorates tacrolimus (FK-506)'s induced immunosupressive effect in rat liver. 2009 Transplant. Proc. pmid:19545748
Hryniewiecka E et al. Arterial hypertension in liver transplant recipients. 2011 Transplant. Proc. pmid:21996217
Grochowicz PM et al. Synergism of castanospermine and FK 506. 1995 Transplant. Proc. pmid:7533408
Weimer R et al. sCD30 and neopterin as risk factors of chronic renal transplant rejection: impact of cyclosporine A, tacrolimus, and mycophenolate mofetil. 2005 Transplant. Proc. pmid:15919463
Reding R et al. Compassionate use of FK 506 in pediatric liver transplantation: a pilot study. 1991 Transplant. Proc. pmid:1721341
Heilman RL et al. Steroid avoidance immunosuppression in low-risk kidney transplant recipients. 2005 Transplant. Proc. pmid:15919466
Lee KK et al. Comparison of short-term immunosuppressive therapy with cyclosporine and FK 506 in small-bowel transplantation. 1990 Transplant. Proc. pmid:1702239
Allers C et al. Tacrolimus, daclizumab, sirolimus, and budesonide after small bowel transplantation in order to reduce nephrotoxicity. 2002 Transplant. Proc. pmid:12034251
Ishikawa T et al. Intestinal function and morphology after ex vivo irradiated small bowel transplantation. 2002 Transplant. Proc. pmid:12034274
Hodge EE et al. Use of mycophenolate mofetil in liver transplant recipients experiencing renal dysfunction on cyclosporine or tacrolimus-randomized, prospective, multicenter study results. 2002 Transplant. Proc. pmid:12176477
Charco R et al. Changes in renal function in long-term survivors of liver transplantation: a comparison between cyclosporine microemulsion and tacrolimus therapy. 2002 Transplant. Proc. pmid:12176478
Ahlmén J et al. Positive effects of tacrolimus in a case of CIDP. 1998 Transplant. Proc. pmid:9865344
Yokoyama I et al. Immunosuppressant effect on Fas antigen expression and p53 of an experimental tumor. 1998 Transplant. Proc. pmid:9865346
Gaber LW et al. Renal histology with varying FK506 blood levels. 1997 Feb-Mar Transplant. Proc. pmid:9122955
Miller J et al. FK 506 in kidney transplantation: results of the U.S.A. randomized comparative phase III study. The FK 506 Kidney Transplant Study Group. 1997 Feb-Mar Transplant. Proc. pmid:9123008
Toyama Y et al. Prolonged small bowel graft survival using photochemotherapy and low-dose FK 506. 1996 Transplant. Proc. pmid:8907924
Hamano I et al. Condyloma Acuminata of the Urethra in a Male Renal Transplant Recipient: A Case Report. 2018 Transplant. Proc. pmid:30316397
Chen CL et al. FK 506 used as rescue therapy for refractory liver allograft rejection. 1994 Transplant. Proc. pmid:7520612
Hebert MF et al. Efficacy and toxicity of FK 506 for the treatment of resistant rejection in liver transplant patients. 1991 Transplant. Proc. pmid:1721373
Eiras G et al. Effects of FK 506 and cyclosporine on T-cell activation: integrin-mediated adhesion of T cells, proliferation, and maturation of cytotoxic T cells. 1991 Transplant. Proc. pmid:1703357
Crespo-Leiro MG Tacrolimus in heart transplantation. 2003 Transplant. Proc. pmid:12962869
Dietl KH Oral dosing of tacrolimus and cyclosporine microemulsion--results from a large multicenter study in renal transplantation. 2002 Transplant. Proc. pmid:12176524
Humar A et al. Surgical complications requiring early relaparotomy after pancreas transplantation: comparison of the cyclosporine and FK 506 eras. 1999 Feb-Mar Transplant. Proc. pmid:10083256
San Miguel C et al. Immunosuppression Strategies in the Treatment of Hepatocellular Carcinoma in Virgen de las Nieves University Hospital. 2015 Transplant. Proc. pmid:26518930
Shapiro R et al. Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. 1997 Transplant. Proc. pmid:9290809
Lee HK et al. Expression of Endoplasmic Reticulum-Mediated Stress Proteins in FK506-Treated T-Lymphocytes. 2016 Transplant. Proc. pmid:27320607
Kumano K et al. Role of the transforming growth factor and monocyte chemoattractant protein in FK506-induced nephropathy in the rat. 1997 Feb-Mar Transplant. Proc. pmid:9123293
Grochowicz PM et al. Synergistic interaction between castanospermine and tacrolimus in a rat heart allograft model. 1997 Feb-Mar Transplant. Proc. pmid:9123296
Wilczek HE et al. Renal transplant histopathologic changes during the first year in patients with tacrolimus (FK 506). 1996 Transplant. Proc. pmid:8962232
Yussim A et al. Conversion from cyclosporine to tacrolimus in hepatic and renal transplantation. 1996 Transplant. Proc. pmid:8962233
Bhaloo S and Prasad GV Severe reduction in tacrolimus levels with rifampin despite multiple cytochrome P450 inhibitors: a case report. 2003 Transplant. Proc. pmid:14611983
Abu-Elmagd KM et al. Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy. 1991 Transplant. Proc. pmid:1721404
Yamada K et al. FK 506-induced juxtaglomerular apparatus hyperplasia and tubular damage in rat kidney--morphologic and biologic analysis. 1992 Transplant. Proc. pmid:1379756
Melter M et al. Successful reconversion from tacrolimus to cyclosporine A Neoral in pediatric liver recipients. 1996 Transplant. Proc. pmid:8769224
Adams CK and Famili P A study of the effects of the drug FK 506 on gingival tissues. 1991 Transplant. Proc. pmid:1721405
Fukuse T et al. Optimal dose of FK 506 in canine lung allotransplantation. 1992 Transplant. Proc. pmid:1379757
Tanaka M et al. Reduction of immunosuppressive agents after living related donor liver transplantation. 1996 Transplant. Proc. pmid:8769268
Ishibashi M et al. Immunopharmacologic effects of immunosuppressive agents explored by a new effector monocyte generation assay. 1989 Transplant. Proc. pmid:2469228
Starzl TE et al. Liver transplantation: an unfinished product. 1989 Transplant. Proc. pmid:2469232
Nakache R et al. Management of massive proteinuria following renal transplantation with mycophenolate mofetil and blood pressure normalization. 2001 Transplant. Proc. pmid:11377533
Baran DA et al. A novel tacrolimus dosing strategy in cardiac transplantation: drug levels, renal function, and biopsy results. 2002 Transplant. Proc. pmid:12176595
Canivet C et al. T-cell function in maintenance renal transplant patients receiving mycophenolate mofetil and steroids with or without tacrolimus. 2008 Transplant. Proc. pmid:19100403
Ettenger R The practical problems of prednisone in pediatric renal transplantation. 2001 Feb-Mar Transplant. Proc. pmid:11267159
Reggiani P et al. Reduced acute rejection after liver transplantation with Neoral-based double immunosuppression. 1998 Transplant. Proc. pmid:9723308
Kuroki H et al. Synergistic effect of FK 506 and donor-specific blood transfusion on rat skin but not on composite tissue (limb) allograft survival. 1991 Transplant. Proc. pmid:1721436
Ju MK et al. Mizoribine versus mycophenolate mofetil in combination therapy with tacrolimus for de novo kidney transplantation: evaluation of efficacy and safety. 2013 Transplant. Proc. pmid:23726602
Todo S et al. Orthotopic liver transplantation in dogs receiving FK-506. 1987 Transplant. Proc. pmid:2445079
Mueller AR et al. Influence of immunosuppression on patient survival after liver transplantation for hepatitis C. 2001 Feb-Mar Transplant. Proc. pmid:11267321
Aktas S et al. Comparison of basiliximab and daclizumab with triple immunosuppression in renal transplantation. 2011 Transplant. Proc. pmid:21440732
Mohamed MA et al. TGF-beta expression in protocol transplant liver biopsies: a comparative study between cyclosporine-A (CyA) and tacrolimus (FK 506) immunosuppression. 2001 Feb-Mar Transplant. Proc. pmid:11267336
Jelassi ML et al. Therapeutic drug monitoring in de novo kidney transplant receiving the modified-release once-daily tacrolimus. 2011 Transplant. Proc. pmid:21440742
Arikan C et al. Allergic disease after pediatric liver transplantation with systemic tacrolimus and cyclosporine a therapy. 2003 Transplant. Proc. pmid:14697973
Cofan F et al. Fatty acid composition in low-density lipoproteins from renal transplant recipients. 1999 Transplant. Proc. pmid:10500603
Cofan F et al. Oxidation of low-density lipoproteins in renal transplant recipients. 1999 Transplant. Proc. pmid:10500604
Ito T et al. Therapeutic Effect of Sirolimus for Lymphangioleiomyomatosis Remaining in the Abdominopelvic Region After Lung Transplantation: A Case Report. Transplant. Proc. pmid:26915883
Lee KM and Eun SC Experimental canine facial transplantation. 2014 Transplant. Proc. pmid:24815162
Manzia TM et al. Ab initio Everolimus-based Versus Standard Calcineurin Inhibitor Immunosuppression Regimen in Liver Transplant Recipients. Transplant. Proc. pmid:29407305
Ikeda M et al. Successful Second Allogeneic Stem Cell Transplantation From a Sibling Donor for Relapse of Myelodysplastic Syndrome in a Recipient of a Renal Transplant From His Mother: Case Report. 2016 Transplant. Proc. pmid:27932152
Sevmis S et al. Tacrolimus-related seizure in the early postoperative period after liver transplantation. 2007 Transplant. Proc. pmid:17524935
Filler G Optimization of immunosuppressive drug monitoring in children. 2007 Transplant. Proc. pmid:17524944
Kolonko A et al. Successful Preemptive Kidney Transplantation With Rituximab Induction in a Patient With Focal Segmental Glomerulosclerosis and Massive Nephrotic Syndrome: A Case Report. 2016 Transplant. Proc. pmid:27932154
Guleria S et al. Tacrolimus (Pan Graf) in live related renal transplantation: an initial experience of 101 recipients in India. 2007 Transplant. Proc. pmid:17445588
Braun F et al. Primary low-dose tacrolimus immunosuppressive prophylaxis for high-risk kidney transplant recipients. 1998 Transplant. Proc. pmid:9636496
Pillet A et al. Monitoring HCMV infection with quantitative real-time PCR in HCMV-positive orthotopic liver transplant recipients, and predictive factors for treatment of the first episode of HCMV viremia. 2006 Transplant. Proc. pmid:16980083
White SA et al. Influence of delayed graft function in renal transplants from cadaveric or non-heart-beating donors. 2000 Transplant. Proc. pmid:10701018
Sens YA et al. Posttransplant diabetes mellitus in renal transplant patients with hepatitis C virus. 2004 Transplant. Proc. pmid:15194304
Williams ST et al. Preliminary analysis of a randomized trial comparing microemulsion cyclosporine and tacrolimus for recipients of renal transplants from non-heart-beating donors. 2000 Transplant. Proc. pmid:10701022
Boggi U et al. Single-center, open, prospective, randomized pilot study comparing cyclosporine versus tacrolimus in simultaneous pancreas-kidney transplantation. 2004 Transplant. Proc. pmid:15194369
Anglicheau D et al. Pharmacogenetics of tacrolimus and sirolimus in renal transplant patients: from retrospective analyses to prospective studies. 2007 Transplant. Proc. pmid:17889118
Stratta RJ et al. Preliminary experience with FK 506 in pancreas transplant recipients. 1995 Transplant. Proc. pmid:8539823